This site is archived and is no longer updated. It will be taken offline in mid-July. All the latest AWMSG recommendations, guidance and information is available on our new website at:
awmsg logo

everolimus (Votubia®)

Reference No. 1156

Publication date:

Appraisal information

everolimus (Votubia®) 2.5 mg tablet
everolimus (Votubia®) 5 mg tablet
everolimus (Votubia®) 10 mg tablet

Company: Novartis Pharmaceuticals UK Ltd
BNF category: Malignant disease and immunosupression
NMG meeting date: Not scheduled
AWMSG meeting date: Not scheduled
Submission Type: Nonsubmission
Status: Not endorsed
Advice No: Not available
Ratification by Welsh Government: 22/05/2013

Current Progress

Ratification by
Welsh Government

AWMSG advice

In the absence of a submission from the holder of the marketing authorisation, everolimus (Votubia®) cannot be endorsed for use within NHS Wales for the treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex who are at risk of complications (based on factors such as tumour size or presence of aneurysm, or presence of multiple or bilateral tumours) but who do not require immediate surgery.
Statement of Advice (SOA)